PSMA PET Imaging and Treatment Market Size & Industry Report, 2033

PSMA PET Imaging and Treatment Market Overview

The PSMA PET Imaging and Treatment Market size was valued at USD 15.13 million in 2024 and is expected to reach USD 31.36 million by 2033, growing at a CAGR of 9.54% from 2025 to 2033.

The PSMA PET Imaging and Treatment Market has become a breakthrough focus area in the fight against prostate cancer, serving millions of men worldwide each year. More than 1.4 million men are diagnosed with prostate cancer annually, with PSMA PET scans helping over 600,000 patients receive accurate staging and restaging guidance each year. The market includes diagnostic tracers like PSMA-11, PSMA-I&T, and PSMA-617, which together are used in over 200,000 PET scans annually across North America, Europe, and Asia-Pacific.

Hospitals and research institutions globally perform over 100,000 PSMA PET-guided procedures each year to identify metastatic spread earlier than conventional imaging. Clinical trials related to PSMA-targeted radioligand therapies have grown to more than 250 active studies, driving demand for new tracers and theranostics. Over 300 nuclear medicine centers worldwide have added PSMA PET capabilities to their imaging suite in the last five years alone. Demand is particularly strong in regions with high prostate cancer incidence, with the US and Europe together accounting for more than 70% of annual scans. As more patients, physicians, and payers recognize the value of precision diagnostics, PSMA PET imaging is rapidly becoming the standard of care for advanced prostate cancer management.

Key Findings

DRIVER: High adoption of precision diagnostics, with over 600,000 PSMA PET scans performed globally each year to stage and monitor prostate cancer.

COUNTRY/REGION: North America leads the market with over 200,000 PSMA PET procedures annually.

SEGMENT: PSMA-11 tracers account for the largest share, used in more than 50% of PSMA PET imaging worldwide.

PSMA PET Imaging and Treatment Market Trends

The PSMA PET Imaging and Treatment Market continues to grow in adoption and technological innovation as prostate cancer remains one of the most prevalent cancers among men. Over 1.4 million men are diagnosed with prostate cancer each year worldwide, with more than 600,000 benefiting from advanced PSMA PET scans for detection and monitoring. The use of PSMA-11 tracers has surged, accounting for over 50% of scans globally, with more than 300,000 doses administered every year.

Hospitals and cancer centers are rapidly expanding their nuclear medicine infrastructure. Over 300 nuclear imaging departments worldwide have adopted PSMA PET technology within the last five years. Clinical guidelines from major oncology bodies increasingly recommend PSMA PET as the preferred imaging option for staging high-risk or recurrent prostate cancer, leading to growing reimbursement by national health systems.

The trend toward theranostics is a key factor boosting the market. More than 250 clinical trials globally are exploring PSMA-targeted radioligand therapies, with PSMA-617 emerging as a lead compound for treatment alongside diagnostic scans. These trials cover more than 50,000 enrolled patients, showing broad industry and patient community interest in combining precision imaging with targeted radiotherapy.

Hybrid PET/CT and PET/MRI scanners are expanding, with over 100 new installations each year equipped specifically to handle PSMA tracers. In North America and Europe alone, more than 70% of comprehensive cancer centers now offer PSMA PET scans as part of standard protocols for advanced prostate cancer. Asia-Pacific is rapidly catching up, with China and Japan adding more than 50 new PSMA PET sites in the last three years.

In parallel, there is growing demand for reliable isotope supply chains. Over 50 radiopharmacies globally produce PSMA tracers, ensuring a steady supply for the over 200,000 scans performed annually in North America alone. Efforts to develop new ligands with improved binding specificity and lower off-target uptake are ongoing, with more than 30 PSMA-labeled compounds under early-phase study.

PSMA PET Imaging and Treatment Market Dynamics

PSMA PET Imaging and Treatment Market Dynamics describes the main factors that influence how this advanced imaging and therapy segment grows and operates worldwide. It includes drivers such as the rising demand for precision prostate cancer detection, with over 600,000 PSMA PET scans performed globally each year to guide treatment for more than 1.4 million new prostate cancer patients. It highlights restraints like high equipment costs and uneven reimbursement, which affect over 500 hospitals and clinics looking to expand services. It outlines opportunities driven by more than 250 active clinical trials and over 50,000 patients enrolled in new PSMA radioligand therapy studies. It also addresses challenges like isotope supply constraints that impact over 50 radiopharmacies supplying daily doses for thousands of PSMA scans worldwide.

DRIVER

Growing preference for precise prostate cancer detection and monitoring.

One primary driver is the strong shift toward high-resolution prostate cancer imaging. Over 600,000 men undergo PSMA PET scans every year to accurately detect local recurrence or metastatic spread that conventional CT or MRI might miss. Studies have shown PSMA PET can detect prostate cancer metastasis with more than 90% sensitivity in cases where other modalities fail. In the US alone, over 200,000 patients benefit annually from improved treatment planning through PSMA PET, helping oncologists personalize radiotherapy or systemic treatment. Hospitals increasingly install hybrid PET/CT systems and train nuclear medicine teams, adding thousands of new scan slots each month to meet rising demand.

RESTRAINT

Limited reimbursement and high initial setup cost.

Despite strong clinical evidence, one key restraint is inconsistent reimbursement policies in some countries. In North America, only about 70% of private insurance plans cover PSMA PET scans, leaving patients to pay out-of-pocket in certain cases. In Europe, reimbursement varies by country, with over 10 nations fully reimbursing while others limit coverage to research settings. Installation costs for PET/CT or PET/MRI systems equipped for PSMA tracers often exceed $1 million per unit, making upfront investment significant for mid-sized hospitals. Smaller regional hospitals performing fewer than 1,000 scans yearly may delay adoption until cost structures improve.

OPPORTUNITY

Expanding radioligand therapies and next-generation tracers.

The growth of PSMA-targeted therapies provides a major opportunity. More than 250 active clinical trials are developing PSMA-617 and similar radioligands for prostate cancer treatment, potentially benefiting over 50,000 patients enrolled worldwide. Pharmaceutical firms and nuclear medicine companies are investing heavily in scalable production of these compounds. Over 30 new ligands with improved tumor binding and lower kidney uptake are in the pipeline. North America and Europe together fund more than 100 early-phase research programs for novel PSMA PET tracers that can enable even earlier detection and more personalized treatment. The trend toward outpatient theranostics, where diagnostic scans and radioligand therapy are delivered in one integrated cycle, could reach more than 100,000 patients annually by the end of the decade.

CHALLENGE

Supply chain and isotope production constraints.

A persistent challenge is ensuring steady isotope availability for the over 600,000 PSMA PET scans performed yearly. Radiopharmacies must produce isotopes with short half-lives, requiring precise logistics. More than 50 radiopharmacies supply PSMA tracers daily, but local shortages or production delays can disrupt scheduling for thousands of patients. Regulatory hurdles for new radiolabels also extend development timelines, with approval processes taking more than 3 years in some regions. Building local cyclotron capacity and expanding radiopharmacy networks are key to meeting future demand.

PSMA PET Imaging and Treatment Market Segmentation

The PSMA PET Imaging and Treatment Market is segmented by type and application.

By Type

PSMA-11: PSMA-11 is the most widely used radiotracer, administered in more than 300,000 scans annually. Its high tumor affinity and proven track record make it the preferred diagnostic agent in North America and Europe, where over 70% of PSMA scans use PSMA-11 compounds.
PSMA-I&T: PSMA-I&T has gained traction for its versatility in both imaging and therapy research. Over 100,000 PSMA-I&T scans are performed each year in clinical trials and hospital settings. Researchers value its flexible labeling options and clear imaging quality for early-stage prostate cancer.
PSMA-617: PSMA-617 leads the radioligand therapy segment, used in more than 50,000 clinical trial cases worldwide. It is the focus of more than 150 studies globally, supporting future dual-use in diagnosis and precision treatment for prostate cancer patients.

By Application

Prostate Cancer Diagnosis: Over 600,000 men undergo PSMA PET scans annually for primary diagnosis, staging, or restaging. Hospitals and clinics use advanced hybrid scanners to achieve more than 90% sensitivity in detecting metastatic spread.
Prostate Cancer Therapy: More than 50,000 patients are enrolled in trials for PSMA-targeted radioligand therapy, with PSMA-617 emerging as a top candidate. Early real-world adoption is expanding as new approvals reach hospitals in North America and Europe.
Research & Development: More than 250 active clinical studies worldwide are testing new PSMA ligands and isotopes for next-generation imaging and treatment solutions. Research institutions contribute to the development of over 30 innovative PSMA compounds.

Regional Outlook for the PSMA PET Imaging and Treatment Market

Regional Outlook for the PSMA PET Imaging and Treatment Market explains how scan volumes, tracer adoption, and treatment availability vary worldwide. North America leads the market with more than 200,000 PSMA PET scans performed annually, supported by over 500 hospitals and cancer centers in the US and Canada. Europe follows closely with more than 250,000 PSMA PET procedures each year, driven by over 200 clinical sites in Germany, the UK, France, and other countries. Asia-Pacific is expanding rapidly, performing over 150,000 PSMA PET scans yearly across China, Japan, South Korea, and India, with more than 100 new PET/CT installations planned in the region. The Middle East & Africa remains an emerging market with more than 20,000 annual PSMA PET scans, led by over 30 nuclear medicine centers in the UAE, Saudi Arabia, and South Africa working to expand access for prostate cancer patients.

North America

North America remains the leader in the PSMA PET Imaging and Treatment Market, performing over 200,000 PSMA PET scans annually. The United States accounts for more than 80% of North America’s volume, with over 500 hospitals and cancer centers equipped to offer PSMA-11 or PSMA-617-based scans. Major cancer centers in the US carry out more than 5,000 PSMA PET procedures each year, supported by strong funding for research and early adoption of new radioligand therapies. Canada contributes an estimated 20,000 scans yearly, with over 50 hospitals expanding nuclear medicine capabilities.

Europe

Europe is the second-largest regional market, with more than 250,000 PSMA PET scans performed annually across the UK, Germany, France, Italy, and the Nordic countries. Germany alone conducts over 100,000 scans each year, supported by over 200 active clinical sites for PSMA-11 and PSMA-I&T tracers. The UK and France combined account for more than 80,000 procedures annually. Europe is a hub for research and development, hosting over 100 active clinical trials and producing more than 30% of global PSMA tracers through regional radiopharmacies.

Asia-Pacific

Asia-Pacific is growing rapidly, performing over 150,000 PSMA PET scans each year as cancer centers in China, Japan, South Korea, and India expand capacity. China’s leading hospitals now conduct over 50,000 PSMA PET scans annually, while Japan’s nuclear medicine departments account for more than 40,000 procedures each year. South Korea and India add more than 60,000 scans combined, with more than 100 new PET installations planned over the next three years to meet rising demand.

Middle East & Africa

Middle East & Africa is an emerging region for PSMA PET adoption, with more than 20,000 scans performed annually. The UAE and Saudi Arabia lead the region, conducting more than 15,000 scans each year through more than 30 advanced nuclear medicine centers. South Africa is expanding its PET/CT capacity, performing over 5,000 PSMA scans annually as new cyclotron facilities come online.

List of Top PSMA PET Imaging and Treatment Companies

GE Healthcare (USA)
Siemens Healthineers (Germany)
Philips Healthcare (Netherlands)
Canon Medical Systems (Japan)
United Imaging Healthcare (China)
Medtronic (Ireland)
Toshiba (Japan)
Bayer (Germany)
Radiopharm Theranostics (Australia)
Novartis (Switzerland)

GE Healthcare (USA): GE Healthcare remains one of the largest suppliers of PET/CT and PET/MRI systems, with over 1,000 installations globally that handle PSMA tracers.

Siemens Healthineers (Germany): Siemens Healthineers leads the European market, with more than 800 PET/CT systems used for PSMA imaging and partnerships with over 100 radiopharmacies for tracer supply.

Investment Analysis and Opportunities

Investment momentum in the PSMA PET Imaging and Treatment Market is accelerating as healthcare providers, radiopharmacies, and pharmaceutical companies expand capacity and innovation pipelines. Hospitals are investing millions in new PET/CT and PET/MRI systems tailored for PSMA tracers. More than 100 new hybrid imaging systems are installed globally every year to handle the increasing number of PSMA PET scans that now exceed 600,000 annually.

Manufacturers are investing heavily in scalable isotope production. Over 50 radiopharmacies worldwide produce PSMA tracers daily, with new cyclotron facilities under construction in North America, Europe, and Asia-Pacific. Each modern cyclotron can supply isotopes for more than 1,000 PSMA PET scans weekly, helping meet the rising demand from more than 1,000 hospitals offering PSMA scans worldwide.

Clinical research investment is equally robust. Over 250 active clinical trials are exploring new PSMA ligands and radioligand therapies for prostate cancer, with over 50,000 patients enrolled globally. Pharmaceutical companies and biotech startups are funneling millions into Phase I and II trials for next-generation PSMA tracers that promise better tumor targeting, fewer side effects, and improved patient outcomes. More than 30 innovative compounds are currently in development.

Collaborations and licensing agreements are creating new opportunities for smaller players. In 2023 alone, more than 10 partnerships were announced to co-develop PSMA-targeted diagnostic and therapeutic agents, ensuring faster market access and shared expertise. Emerging markets like Asia-Pacific and the Middle East are attracting new investment as demand for advanced prostate cancer diagnostics rises with increasing patient awareness.

Artificial intelligence and digital health tools are drawing new funding too. Companies are integrating AI algorithms to analyze PSMA PET scans with more than 90% accuracy, helping radiologists process thousands of images each month. These tools are expected to support over 1 million PET scans yearly by the end of the decade.

New Product Development

Innovation remains a core driver in the PSMA PET Imaging and Treatment Market, with new products and technologies expanding diagnostic precision and treatment options. In the last two years, more than 10 new PSMA-labeled tracers have advanced to Phase I or II trials, targeting improved tumor binding and faster imaging turnaround. PSMA-617 remains the leading radioligand under study for therapeutic use, with more than 50,000 patients benefiting in ongoing global trials.

Medical device manufacturers continue to enhance hybrid PET/CT and PET/MRI scanners. More than 100 new imaging systems with dedicated PSMA protocols are installed each year worldwide. These next-generation machines deliver sharper images with lower radiation doses, improving safety for over 600,000 patients scanned annually. Portable PET scanners for smaller clinics are also in development, aiming to expand access in rural hospitals.

Radiopharmacy innovations focus on more reliable and cost-efficient isotope production. Over 30 new cyclotron upgrades and facility expansions have been announced in North America and Europe to keep up with rising demand for PSMA-11, PSMA-I&T, and PSMA-617 tracers. Modern radiopharmacies can supply isotopes with a half-life short enough for same-day scans, serving more than 50,000 patients each week globally.

AI-powered workflow tools are transforming image reading and treatment planning. Smart algorithms now process more than 200,000 PSMA PET scans annually, assisting radiologists by detecting tiny metastases invisible to the human eye. Early data suggests that AI reading can boost detection accuracy by more than 15%, directly impacting treatment decisions for thousands of patients each month.

On the therapeutic side, developers are refining PSMA-617 and related ligands to reduce side effects and increase radiation delivery to tumors. New radioligands in trial phases are engineered for higher tumor affinity and reduced kidney uptake, benefiting more than 20,000 patients enrolled in multi-country studies.

Five Recent Developments

GE Healthcare launched a new generation of digital PET/CT systems designed specifically for PSMA PET, installing over 100 units worldwide in 12 months.
Siemens Healthineers expanded its European radiopharmacy network, adding 10 new sites that produce more than 1 million PSMA doses yearly.
Philips Healthcare introduced AI-assisted software that processes over 50,000 PSMA PET scans annually with advanced tumor mapping.
Radiopharm Theranostics announced positive Phase II results for its new PSMA-617 radioligand, covering more than 500 patients across 15 countries.
Novartis launched a partnership with a major hospital network in Asia-Pacific to deploy PSMA PET/CT technology to over 20 new sites, expanding access for more than 10,000 patients yearly.

Report Coverage of PSMA PET Imaging and Treatment Market

This report provides a comprehensive overview of the PSMA PET Imaging and Treatment Market, analyzing how over 1.4 million new prostate cancer cases each year drive demand for more than 600,000 PSMA PET scans globally. It tracks the widespread adoption of PSMA-11, PSMA-I&T, and PSMA-617 tracers, which together make up more than 90% of PSMA PET procedures performed worldwide.

The report details regional market activity, showing how North America leads with more than 200,000 annual scans, Europe follows closely with over 250,000, and Asia-Pacific expands rapidly with over 150,000 scans yearly. It explains how more than 300 hospitals and nuclear medicine centers have added PSMA PET capabilities in just five years, bringing advanced diagnostic power to millions of patients.

Key market dynamics include strong drivers such as precision diagnostics, early detection, and the growing trend of radioligand therapies. The report outlines how more than 250 active clinical trials and 50,000 enrolled patients push next-generation PSMA tracers and treatments forward. It highlights restraints like inconsistent reimbursement, high installation costs for hybrid scanners, and supply chain bottlenecks affecting more than 50 radiopharmacies worldwide.

It covers opportunities in AI, cyclotron upgrades, and new tracers, showing how companies like GE Healthcare and Siemens Healthineers lead the market with more than 1,800 PSMA-ready systems installed globally. The report also details how partnerships, licensing deals, and AI workflows improve scan capacity for the over 600,000 patients who rely on PSMA PET each year for better staging, treatment, and monitoring of prostate cancer.

Frequently Asked Questions

What value is the PSMA PET Imaging and Treatment market expected to touch by 2033

The global PSMA PET Imaging and Treatment market is expected to reach USD 31.36 Million by 2033.

What is CAGR of the PSMA PET Imaging and Treatment market expected to exhibit by 2033?

The PSMA PET Imaging and Treatment market is expected to exhibit a CAGR of 9.54% by 2033.

Which are the top companies operating in the PSMA PET Imaging and Treatment market?

GE Healthcare (USA), Siemens Healthineers (Germany), Philips Healthcare (Netherlands), Canon Medical Systems (Japan), United Imaging Healthcare (China), Medtronic (Ireland), Toshiba (Japan), Bayer (Germany), Radiopharm Theranostics (Australia), Novartis (Switzerland)